Uji klinis Melanoma di Delaware
6 studi untuk Melanoma mencari peserta di lokasi di Delaware.
Kota di Delaware
Teks studi resmi (Bahasa Inggris)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05136196Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Beebe Medical Center, Lewes
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- dan 4 lainnya
Menerima pesertaFase 3
Usia 75 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07068074A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- Alfred I duPont Hospital for Children, Wilmington
Menerima pesertaFase 2
Hingga usia 25 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT07621614Project: Every Child for Younger Patients With Cancer
- Alfred I duPont Hospital for Children, Wilmington
Menerima pesertaStudi observasional
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT02402244Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- dan 1 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Newark
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.